These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 25889520)

  • 21. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of positron emission tomography/computed tomography for adjuvant chemotherapy of colon cancer.
    Baik H; Lee SM; Seo SH; An MS; Kim KH; Bae KB; Oh MK; Hong KH
    ANZ J Surg; 2018 Jun; 88(6):587-591. PubMed ID: 28687025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor.
    Hugen N; Verhoeven RH; Lemmens VE; van Aart CJ; Elferink MA; Radema SA; Nagtegaal ID; de Wilt JH
    Int J Cancer; 2015 Jan; 136(2):333-9. PubMed ID: 24841868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis.
    Powers BD; Felder SI; Imanirad I; Dessureault S; Dineen SP
    J Gastrointest Cancer; 2021 Jun; 52(2):719-727. PubMed ID: 32743731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators.
    Bardia A; Loprinzi C; Grothey A; Nelson G; Alberts S; Menon S; Thome S; Gill S; Sargent D
    Semin Oncol; 2010 Feb; 37(1):39-46. PubMed ID: 20172363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.
    Karoui M; Gallois C; Piessen G; Legoux JL; Barbier E; De Chaisemartin C; Lecaille C; Bouche O; Ammarguellat H; Brunetti F; Prudhomme M; Regimbeau JM; Glehen O; Lievre A; Portier G; Hartwig J; Goujon G; Romain B; Lepage C; Taieb J;
    Colorectal Dis; 2021 Jun; 23(6):1357-1369. PubMed ID: 33580623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
    Chen D; Wen X; Song YS; Rhee YY; Lee TH; Cho NY; Han SW; Kim TY; Kang GH
    Clin Epigenetics; 2016; 8():36. PubMed ID: 27051466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
    Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ
    Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
    Salem ME; Yin J; Goldberg RM; Pederson LD; Wolmark N; Alberts SR; Taieb J; Marshall JL; Lonardi S; Yoshino T; Kerr RS; Yothers G; Grothey A; Andre T; De Gramont A; Shi Q
    Ann Oncol; 2020 Apr; 31(4):480-486. PubMed ID: 32085892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
    Emile JF; Julié C; Le Malicot K; Lepage C; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Dimet S; Boulagnon-Rombi C; Allard MA; Penault-Llorca F; Bennouna J; Laurent-Puig P; Taieb J; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    Eur J Cancer; 2017 Sep; 82():16-24. PubMed ID: 28651158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy.
    Noh OK; Oh SY; Kim YB; Suh KW
    World J Surg; 2017 Nov; 41(11):2898-2905. PubMed ID: 28707088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
    Hendlisz A; Golfinopoulos V; Deleporte A; Paesmans M; Mansy HE; Garcia C; Peeters M; Annemans L; Vandeputte C; Maetens M; Borbath I; Dresse D; Houbiers G; Fried M; Awada A; Piccart M; Laethem JL; Flamen P
    BMC Cancer; 2013 Apr; 13():190. PubMed ID: 23587148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
    J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer.
    Maisano R; Azzarello D; Maisano M; Mafodda A; Bottari M; Egitto G; Nardi M
    J Chemother; 2012 Aug; 24(4):212-6. PubMed ID: 23040685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
    Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
    J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
    André T; Boni C; Navarro M; Tabernero J; Hickish T; Topham C; Bonetti A; Clingan P; Bridgewater J; Rivera F; de Gramont A
    J Clin Oncol; 2009 Jul; 27(19):3109-16. PubMed ID: 19451431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution.
    Misirlioglu HC; Coskun-Breuneval M; Kucukpilakci B; Ugur VI; Elgin Y; Demirkasimoglu T; Kara SP; Ozgen A; Sanri E; Guney Y
    Asian Pac J Cancer Prev; 2014; 15(20):8871-6. PubMed ID: 25374221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.